🟢 RARE Surges 4.5% on Renewed Analyst Optimism and Key Pipeline Developments
Ultragenyx
Ultragenyx Pharmaceutical (RARE) is trading 4.5% up at $30.43 today, driven by renewed analyst interest and ongoing pipeline advancements.
Cantor Fitzgerald reiterated an Overweight rating and raised its price target, highlighting the gene therapy candidate GTX-102 for Angelman syndrome as a key asset.
The FDA's acceptance of the resubmitted BLA for UX111, with a PDUFA decision date of September 19, 2026, continues to add a defined regulatory milestone to the company's pipeline.
